ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2453

The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices

Megan E. B. Clowse1, Amanda M. Eudy2, Bonnie L. Bermas3, Eliza Chakravarty4, Lisa R. Sammaritano5 and Christina D. Chambers6, 1Rheumatology, Duke University School of Medicine, Durham, NC, 2Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Edmond, OK, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Pediatrics, University of California, San Diego, La Jolla, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Hydroxychloroquine, Neonatal lupus and pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Reproductive Issues in Rheumatic Disorders - Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: There are presently no official guidelines about the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro antibodies. The objective of this study was to survey an international sample of providers to determine their current practices.

Methods:  A survey was designed by the organizing committee of the 9thInternational Conference or Reproduction, Pregnancy and Rheumatic Diseases. The survey was sent to 330 people who had attended prior conferences or were registered for this conference, were authors of recent publications on rheumatic diseases and pregnancy, or were authors of abstracts on rheumatic diseases and pregnancy from the ACR meetings in 2012, 2013, and 2014. Respondents who did not provide demographic information were excluded from the final analysis (n=11).

Results:   There were 48 respondents. Most (55%) follow >15 pregnancies in rheumatic patients per year, and 33% were practicing rheumatologists for >15 years. Most were university-based physicians (88%) and from North America (42%) or Europe (42%). Screening: For anti-Ro/SSA positive women, 80% recommended serial fetal ECHOs, with most starting at gestational week 16 (59%) and stopping at week 28 (25%), although the time to stop varied widely between weeks 22 and 34. For women without a prior infant with neonatal lupus, respondents recommend every other week (44%) or weekly (28%) fetal ECHOs, and 5% of respondents preferred a plan of two fetal echoes. For women with a prior infant with neonatal lupus, 80% recommend weekly fetal ECHOs. Prevention: Hydroxychloroquine was recommended by 67% of respondents to prevent CHB and most would recommend starting the drug prior to pregnancy (62%). Treatment: Respondents were asked about medications for varying degrees of CHB in a 20-week pregnant, anti-Ro and La positive SLE patient.Respondents recommended dexamethasone (53%) or HCQ (43%) for 1st degree HB; dexamethasone (88%) for 2nd degree HB; and dexamethasone (55%), IVIg (33%), or no therapy (27%) for complete HB. When dexamethasone was started for 2nd degree CHB, 58% would stop dexamethasone if it progressed to complete heart block, 47% would stop if heart block disappeared, and 24% would stop if the 2nd degree CHB remained.

Conclusion:  Despite the absence of official guidelines, many physicians with a focus on pregnancy and rheumatic disease have developed similar patterns in the screening, prevention, and treatment of CHB. These include serial fetal ECHOs, preventive HCQ, and treatment of early heart block with dexamethasone. These practices are not uniform, however, and have not been formally tested in prospective trials. The next step in this field must include testing of these approaches to identify the most cost effective and efficacious plan for these pregnancies.


Disclosure: M. E. B. Clowse, Pfizer, Janssen, 2,UCB Pharma, 5; A. M. Eudy, GSK, 5; B. L. Bermas, UptoDate, 7; E. Chakravarty, None; L. R. Sammaritano, None; C. D. Chambers, None.

To cite this abstract in AMA style:

Clowse MEB, Eudy AM, Bermas BL, Chakravarty E, Sammaritano LR, Chambers CD. The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-prevention-screening-and-treatment-of-congenital-heart-block-from-neonatal-lupus-a-survey-of-provider-practices/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevention-screening-and-treatment-of-congenital-heart-block-from-neonatal-lupus-a-survey-of-provider-practices/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology